Clinical trials: Acute ST Elevation Myocardial Infarction
Cardiogenic Shock, Acute Myocardial Infarction
National Cardiogenic Shock Initiative
This study evaluates the use of early mechanical circulatory support in patients presenting with acute myocardial infarction and cardiogenic shock.
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCSI (NCT03677180)
- Where
- 75 sites in United States
- Volunteers
- 406 people
- Sponsor
- Henry Ford Health System
Myocardial Infarction
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients…
- Trial name
- NCT00433966
- Testing
- Bivalirudin, Unfractionated heparin, Bare metal stent
- Where
- United States
- Volunteers
- 3,602 people
- Sponsor
- Cardiovascular Research Foundation, New York
Coronary Artery Disease, Acute Myocardial Infarction With ST-segment Elevation
Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction
The aim of the study is to prove that early discharge (within 72 hours) in selected group of patients after myocardial infarction with elevations of ST-segment is feasible and safe
- Conditions
- Coronary Artery Disease, Acute Myocardial Infarction With ST-segment Elevation, Primary Percutaneous Coronary Intervention, Early Discharge
- Trial name
- NCT02023983
- Testing
- Early discharge, Standard discharge
- Where
- Czechia
- Volunteers
- 151 people
- Sponsor
- Kamil Novobílský
Acute ST Elevation Myocardial Infarction
REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction
The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.
- Trial name
- NCT00378352
- Testing
- Epoetin alfa
- Where
- 16 sites in United States
- Volunteers
- 223 people
- Sponsor
- National Institute on Aging (NIA)
Myocardial Infarction, Acute Coronary Syndrome
Diagnostic Accuracy of Electrocardiogram for Acute Coronary Occlusion Resulting in Myocardial Infarction
The decision of emergency reperfusion of a suspected acute coronary artery occlusion by means of percutaneous coronary intervention or intravenous thrombolytics depends on the presence of a certain amount of ST-segment elevation…
- Conditions
- Myocardial Infarction, Acute Coronary Syndrome, Coronary Artery Disease
- Trial name
- DIFOCCULT (NCT04022668)
- Testing
- Coronary angiogram
- Where
- Turkey (Türkiye)
- Volunteers
- 3,000 people
- Sponsor
- Yeditepe University
ST Elevation Myocardial Infarction (STEMI), Coronary Artery Disease
Metformin to Reduce Heart Failure After Myocardial Infarction
The investigators will evaluate the effect of metformin therapy during 4 months in non-diabetic patients following ST-elevation myocardial infarction on left ventricular ejection fraction as measured with cardiac magnetic…
- Conditions
- ST Elevation Myocardial Infarction (STEMI), Coronary Artery Disease, Heart Failure, Diabetes
- Trial name
- GIPS-III (NCT01217307)
- Testing
- Metformin
- Where
- Netherlands
- Volunteers
- 380 people
- Sponsor
- University Medical Center Groningen
Myocardial Ischemia, Acute Coronary Syndrome
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention…
- Trial name
- NCT00089895
- Testing
- Eptifibatide (Integrilin)
- Volunteers
- 9,406 people
- Sponsor
- Organon and Co
Acute Myocardial Infarction
Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction
Acute myocardial infarction is characterized by an intense inflammatory response. The degree of the response influences clinical outcome, with 'more' inflammation promoting heart failure.
- Trial name
- VCU-Alpha1RT (NCT01936896)
- Testing
- Alpha 1-Antitrypsin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Heart Attack
P3AMI Antiplatelet Trial
Major heart attacks are caused by a numerous factors, including sudden clot formation in a coronary artery leading to a blockage and heart muscle death. The clots are largely made of sticky clotting blood cells (platelets).
- Trial name
- NCT02376283
- Testing
- Prasugrel, Clopidogrel, ticagrelor
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Acute Myocardial Infarction
Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction
The main objective is to compare a fibrinolytic strategy with an interventional strategy initiated as early as possible, preferably in the pre-hospital phase, with respect to resolution of ST-segment elevation at 120 minutes…
- Trial name
- SWEDES (NCT00806403)
- Testing
- reteplase 10+10 U, primary PCI
- Where
- 5 sites in Sweden
- Volunteers
- 205 people
- Sponsor
- Sahlgrenska University Hospital
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
Acute Coronary Syndromes
A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary…
- Trial name
- ACCOAST (NCT01015287)
- Testing
- Prasugrel
- Where
- 153 sites in Austria, Belgium and 17 more
- Volunteers
- 4,033 people
- Sponsor
- Eli Lilly and Company
ST Segment Elevation Acute Myocardial Infarction
Anakinra to Prevent Post-infarction Remodeling
Thousands of patients die daily from early and late complications of a heart attack (acute myocardial infarction, AMI). Patients surviving AMI remain at high risk of death from adverse cardiac remodeling (dysfunction and…
- Trial name
- VCU-ART (NCT00789724)
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Acute Myocardial Infarction
Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)
This study will evaluate change in heart muscle function from baseline to three months and twelve months in participants who present with a heart attack and a completely occluded coronary artery.
- Trial name
- NCT01324453
- Testing
- Post Conditioning + Primary PCI, Standard Primary PCI
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Minneapolis Heart Institute Foundation
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Acute ST Segment Elevation Myocardial Infarction
Platelet Function in Resuscitated Patients
Approx. 65% of resuscitated patients at the intensive care unit for internal medicine are due to myocardial infarction. Almost all patients are initially diagnosed and treated in the cath lab.
- Trial name
- NCT02914795
- Testing
- diagnostic analysis of platelet function
- Where
- Austria
- Volunteers
- 99 people
- Sponsor
- Medical University of Graz
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Myocardial Infarction, Multivessel Coronary Artery Disease
Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD.
The Compare-Acute trial is a prospective randomised trial in patients with multivessel disease, who are admitted into hospital with a ST-elevation Myocardial Infarction.
- Trial name
- CompareAcute (NCT01399736)
- Testing
- FFR-guided revascularisation strategy, randomised to guidelines group
- Where
- 26 sites in Czechia, Germany and 6 more
- Volunteers
- 885 people
- Sponsor
- Maasstad Hospital
AMI
Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction
Primary objective: To demonstrate that in hyperglycemic subjects with anterior STEMI (ST Elevation Myocardial Infarction) undergoing Percutaneous Coronary Intervention (PCI), tight glycemic control using insulin glulisine and…
- Trial name
- INTENSIVE (NCT00670228)
- Testing
- Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
- Where
- 5 sites in United States, Argentina and 3 more
- Volunteers
- 34 people
- Sponsor
- Sanofi